Personalized treatment approaches for a rare type of Hodgkin lymphoma
Investigating personalized approaches to de-intensify therapy for nodular lymphocyte-predominant Hodgkin lymphoma
['FUNDING_CAREER'] · STANFORD UNIVERSITY · NIH-10948864
This study is looking to create personalized treatment plans for people with nodular lymphocyte-predominant Hodgkin lymphoma by examining their tumor and blood samples to find out which therapies might work best for them, helping to reduce side effects while still being effective.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-10948864 on ClinicalTrials.gov |
What this research studies
This research focuses on developing personalized treatment strategies for patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). By analyzing tumor and blood samples, the study aims to identify specific genomic and microenvironmental factors that can predict how well patients will respond to different therapies. The approach combines expertise in cancer biology, biostatistics, and predictive modeling to optimize treatment plans, potentially reducing the intensity of therapy while maintaining effectiveness. Patients may benefit from a more tailored approach to their treatment, which could lead to fewer side effects and better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma who are seeking personalized treatment options.
Not a fit: Patients with other types of Hodgkin lymphoma or those who do not have a diagnosis of lymphoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less intensive treatment options for patients with nodular lymphocyte-predominant Hodgkin lymphoma.
How similar studies have performed: Previous research has shown promise in using genomic and microenvironmental factors to personalize cancer treatment, indicating that this approach could be beneficial.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BINKLEY, MICHAEL S — STANFORD UNIVERSITY
- Study coordinator: BINKLEY, MICHAEL S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.